|Home | About | Journals | Submit | Contact Us | Français|
Over one-quarter of adult Americans are diagnosed with a mental illness like Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), schizophrenia, and Alzheimer’s Disease. In addition to the exceptional personal burden these disorders exert on patients and their families, they also have enormous cost to society. Although existing pharmacological and psychosocial treatments alleviate symptoms in many patients, the comorbidity, severity, and intractable nature of mental disorders strongly underscore the need for novel strategies. As the hippocampus is a site of structural and functional pathology in most mental illnesses, a hippocampal-based treatment approach has been proposed to counteract the cognitive deficits and mood dysregulation that are hallmarks of psychiatric disorders. In particular, preclinical and clinical research suggests that hippocampal neurogenesis, the generation of new neurons in the adult dentate gyrus, may be harnessed to treat mental illness. There are obvious applications and allures of this approach; for example, perhaps stimulating hippocampal neurogenesis would reverse the overt and noncontroversial hippocampal atrophy and functional deficits observed in Alzheimer’s Disease and schizophrenia, or the more controversial hippocampal deficits seen in MDD and PTSD. However, critical examination suggests that neurogenesis may only correlate with mental illness and treatment, suggesting targeting neurogenesis alone is not a sufficient treatment strategy. Here we review the classic and causative links between adult hippocampal neurogenesis and mental disorders, and provide a critical evaluation of how (and if) our basic knowledge of new neurons in the adult hippocampus might eventually help combat or even prevent mental illness.
Each year over 25% of adult Americans carry the diagnosis of at least one mental disorder (Kessler et al., 2005a; Kessler et al., 2005b). By far, the greatest percentage of the adult US population – 18.7% – is diagnosed with an anxiety disorder like Post-Traumatic Stress Disorder (PTSD, 3.5%), but notable percentages of the population are also diagnosed with mood disorders (9.5%) like Major Depressive Disorder (MDD, 6.7%), or with Alzheimer’s Disease (~2%) and schizophrenia (1.1%) (Kessler et al., 2005a; Kessler et al., 2005b). Combined with psychosocial support, pharmacological interventions like anxiolytic, antidepressive, and antipsychotic drugs alleviate many symptoms associated anxiety disorders, MDD, and schizophrenia, respectively. However, the persistence and severity of symptoms of these individual disorders, the high proportion of individuals with comorbid psychiatric disorders, like addiction, or other severe health challenges, like obesity or cardiovascular disease, results in enormous personal and societal cost. Therefore, there is extraordinary interest in identifying and pursuing novel strategies for the treatment and even prevention of mental illness.
While mental disorders are exceptionally diverse and likely have discrete and complex neurobiological underpinnings, one particular brain region has long been studied for its potential involvement in mental illness in general: the hippocampus (Figure 1) (Bloom, 1975; Bloom, 1984; Frith and Done, 1988; Holsboer, 1988; Kling et al., 1987; McEwen et al., 1992; Meaney et al., 1988). Primarily known for its role in learning and memory, the hippocampus also has an important role in general cognition, mood regulation, response to stress, and even in encoding predictions for future events (Bast, 2007; Eichenbaum and Fortin, 2009; Fuchs and Flugge, 1998; Price and Drevets, 2009; Squire, 2004). A large body of literature shows that, in general, mental illness is marked by diminished hippocampal structure and function. For example, MDD, PTSD, schizophrenia, Alzheimer’s disease and even stress – a precipitating factor in many mental disorders – are marked by decreased hippocampal volume, learning and memory deficits, and mood dysregulation (e.g. Bremner, 1999; Campbell and Macqueen, 2004; Geuze et al., 2005; Goldman and Mitchell, 2004; Liberzon and Sripada, 2008; Lupien et al., 2007b; Pfefferbaum and Marsh, 1995; Sala et al., 2004; Sapolsky, 2000b; Savitz and Drevets, 2009; Villarreal and King, 2001). Intriguingly, successful improvement of the behavioral and cognitive symptoms of these disorders is often linked to attenuation or reversal of these changes in hippocampal structure and function. Such work has encouraged consideration of whether hippocampal atrophy is a useful target for the treatment of mental illness (Dhikav and Anand, 2007; Sala et al., 2004; Sapolsky, 2000a).
The hippocampus is one of most “responsive” brain structures in that it demonstrates rapid plasticity at the molecular, cellular, structural, and functional levels after specific stimuli. Thus, it has been challenging for scientists to narrow which aspect of hippocampal plasticity might be best targeted to counteract the symptoms of such diverse disorders. One particular aspect of hippocampal plasticity that has received significant attention is adult hippocampal neurogenesis, or the ability of the hippocampus to generate new neurons throughout life. First discovered by Joseph Altman more than forty-five years ago (Altman, 1963), it is now accepted that stem-like and progenitor cells residing in the aptly-named subgranular zone (SGZ; Figure 1) give rise to dentate gyrus granule neurons that integrate into circuitry and contribute to discrete aspects of hippocampal functions (Balu and Lucki, 2009; Pathania et al., in press). As reviewed in detail elsewhere (Abrous et al., 2005; Kempermann et al., 2008) and briefly here (Table 1), there is an enormous amount of correlative evidence linking hippocampal neurogenesis with mental disorders. More recent work has provided striking causative links as well (e.g. Li et al., 2008b; Revest et al., 2009; Santarelli et al., 2003). The surge of primary and review papers on this topic urge revisiting the question, “Is manipulation of hippocampal neurogenesis a promising target for the treatment of mental disorders?”
A number of excellent reviews have recently tackled questions including “What is neurogenesis good for?” and “Is targeting hippocampal atrophy useful for mental illness?” (e.g. Aimone et al., 2006; Becker and Wojtowicz, 2007; Bruel-Jungerman et al., 2007; Drew and Hen, 2007; Eisch et al., 2008; Elder et al., 2006; Gould et al., 1999; Kempermann et al., 2008; Kempermann and Kronenberg, 2003; Ming and Song, 2005; Morgan, 2007; Perera et al., 2008; Sahay and Hen, 2007; Thomas and Peterson, 2008; Thompson et al., 2008; Vaidya et al., 2007). Therefore, the goal for this brief review is to critically evaluate hippocampal neurogenesis as a viable treatment aim and to provide an “update” to previous reviews that have been more narrowly focused on individual psychiatric disorders, such as depression (e.g. Drew and Hen, 2007, Feldmann, 2007 #10060) or schizophrenia/DISC1 (e.g. Dranovsky and Hen, 2007). While the preponderance of literature to date has provided insight into psychiatric illnesses through rodent models, there is surprisingly little known about normal and pathological neurogenesis in humans. Much recent work in human neurogenesis focuses on seizure activity and epilepsy, known to robustly increase neurogenesis in both rodents and humans. However, the lack of data on other human psychiatric illnesses has not been emphasized elsewhere, and another stated purpose of the current review is to highlight how little is known regarding the human diseases. We critically evaluate the hopes in targeting adult hippocampal neurogenesis for treating mental disorders, then highlight major obstacles to overcome before translational applications of adult hippocampal neurogenesis can be realized. We particularly hope this review will engage those readers outside the fields of adult neurogenesis and mental illness research, because stimulating interdisciplinary research is likely critical to future integration of our basic knowledge of new cells in the adult brain with clinical need.
The hippocampus is one of two well-accepted regions of the adult brain in which new neurons are added through mammalian life. While the human and rodent hippocampi maintain the same basic anatomic regions (Figure 1A–C), the process of neurogenesis has been best characterized within the rodent dentate gyrus and has been the subject of many extensive reviews. However, we would be remiss if we did not provide essential information regarding basic progression of neurogenic stages. The reader is strongly encouraged to see the supplemental material for a more detailed (albeit still abbreviated) discussion of the hallmark stages of proliferation, maturation, and survival of hippocampal progenitors (see “Adult hippocampal neurogenesis: where, how, and for what purpose?” in Supplemental Information).
In brief, neurogenesis proceeds in the adult hippocampus but is restricted to the subgranular zone (SGZ) of the dentate gyrus (Figure 1D). Along the border of the granule cell layer and the hilus, stem-like cells (referred to as Type-1 cells, Type B cells, or quiescent neural precursors) putatively divide asymmetrically to produce daughter precursor cells (called Type-2 cells, Type D cells, or transiently-amplifying progenitor cells). Type-2 and their slightly more mature counterparts (called Type-3 cells or neuroblasts) divide frequently and constitute the majority of dividing cells within the SGZ. In a process that remains poorly understood, proliferative neuroblasts become post-mitotic and differentiate into immature neurons. During this process, immature neurons mature and extend dendritic branches into the molecular layer to receive synaptic input from the perforant pathway and also extend a nascent axon through the hilus to the CA3 region of the hippocampus via the mossy fiber pathway. Over the course of several weeks to months, adult-born neurons survive and incorporate into the hippocampal circuitry. Cell-intrinsic and -extrinsic factors governing neurogenesis, as well as the role of neurotransmitters, are reviewed elsewhere within this issue (Pathania et al., in press).
Several facets of neurogenesis remain elusive. In particular, hippocampal stem-like cells have been difficult to study in part because they divide infrequently and the putative stem cells express markers of immature astrocytes and maintain unique morphology with an irregularly-shaped soma and an elaborate series of processes in the inner molecular layer. Also, it remains unclear at which point progenitor cells become fated to become neurons. Under culture conditions, hippocampally-derived progenitors can differentiate into three hallmark lineages, including neurons, astrocytes, and oligodendrocytes (Table 1, far right column). However, under normal conditions in vivo, the vast majority (70–90%) of surviving adult-born cells become neurons. In addition, the behavioral and functional significance of adult neurogenesis remain poorly understood, though recent studies emphasize that new granule neurons may play a role in discrete hippocampal memory tasks and in aspects of mood regulation.
Adult hippocampal neurogenesis has been suggested as a target for the amelioration or prevention of mental illness (Balu and Lucki, 2009; Kaneko and Sawamoto, 2009). Each of the psychiatric disorders discussed here – MDD, PTSD, Alzheimer’s Disease, and schizophrenia – is linked to decreased hippocampal volume and function. As summarized in Table 1, an enormous amount of evidence links animal models of mental illness to altered hippocampal neurogenesis. Here we provide a selective review of this preclinical work alongside translational work in human and non-human primates for MDD, PTSD, schizophrenia and Alzheimer’s Disease to highlight why researchers are so excited about the prospect of reversing deficits in hippocampal neurogenesis to treat these disorders.
In humans, stress often precipitates or exacerbates mental illness. Thus, animal models of MDD and PTSD generally use stress to elicit behavioral phenotypes approximating clinical symptoms (Bremner, 2006; Greenwood and Fleshner, 2008; Krishnan and Nestler, 2008; Stam, 2007; Takemura and Kato, 2008). Animal models of MDD and PTSD almost ubiquitously result in acute suppression of in vivo and in vitro proliferation and in vivo survival of hippocampal neurons, and treatments like antidepressant drugs and exercise can reverse these changes (Banasr and Duman, 2007; Feldmann et al., 2007; Perera et al., 2008; Sahay and Hen, 2007; Sahay and Hen, 2008; Schloesser et al., 2009; Thomas and Peterson, 2008; Vollmayr et al., 2007; Wang et al., 2008). However, while suppression of hippocampal neurogenesis alone does not result in a depressive phenotype (e.g. Airan et al., 2007; David et al., 2009), adult-generated hippocampal neurons appear to play a role in some aspects of mood regulation. Interestingly, loss of adult-born neurons may interfere with the efficacy of antidepressant drugs (Santarelli et al., 2003). However, since loss of antidepressant efficacy is likely drug-, behavior- and species-specific and has not been demonstrated in all models of diminished neurogenesis or models of depression (e.g. David et al., 2009; Holick et al., 2008; Singer et al., 2009; Surget et al., 2008), far more work is needed on this topic.
While preclinical models of MDD and PTSD generally show decreased hippocampal proliferation and survival immediately after the stressful experience, the clinical effects are still unclear. Initial work on post-mortem tissue found no change in proliferation in MDD patients (Reif et al., 2006). Another recent report has replicated that there is no decrease in proliferating Ki-67 cells between MDD and control samples (Boldrini et al., 2009), and recent data indicate that antidepressant treatments enhance discrete facets of neurogenesis in human and non-human primate models (Boldrini et al., 2009; Perera et al., 2007). Unfortunately, there are many aspects of these and other postmortem experiments that urge caution in their interpretation. These include low sample size, lack of information on agonal index or serum toxicology at death, and variations in the region of the hippocampus chosen for analysis. Thus, firm conclusion on the relationship between depression and neurogenesis awaits assessment in other studies. It is reasonable however at this juncture to indicate the following striking links: clinical and preclinical data support that the depressed disease state does not correlate with diminished neurogenesis, whereas treatment of the disease state may result in normalization or enhancement of neurogenesis.
Clearly, more studies in clinical and preclinical paradigms are required. In addition to the call raised above for more detailed human post-mortem experiments, additional basic and clinical research is required to identify how neurogenesis is altered basally in MDD and PTSD, and how effective pharmacobehavioral therapy might differentially alter neurogenesis. In addition, the hypothesis that adult-generated neurons are required for antidepressant efficacy (Santarelli et al., 2003) still needs to be sufficiently addressed through humans, primate, and rodent studies, particularly in light of more recent work from the same group that may draw the generality of this hypothesis into question (David et al., 2009; Holick et al., 2007; Surget et al., 2008). However, the enormity of the correlative and the emerging causative links between adult hippocampal neurogenesis and MDD, PTSD and stress provides a remarkable amount of fuel for this ongoing research effort.
It has long been known that the hippocampus is target for neurodegeneration in Alzheimer’s Disease, and imaging studies now support that the hippocampus is among the first brain areas influenced during disease progression. While links between Alzheimer’s Disease and neurogenesis have also long been proposed (German and Eisch, 2004), the direction of the relationship remains highly controversial due to the opposing results that have emerged from animal models of the disorder (Table 1) and work with tissue from Alzheimer’s Disease patients.
For example, discrete stages of neurogenesis are decreased in certain mouse models (Donovan et al., 2006; Zhang et al., 2007), but increased in other mouse models (Jin et al., 2004a; Yu et al., 2009). The attention to effect of neurogenic stages has particularly paid off here, as some studies have shown that proliferation is decreased but survival of ectopic granule cell neurons is actually enhanced (Donovan et al., 2006), while other have shown that proliferation is increased although the cells have delayed maturation (Li et al., 2008a). The human work has been similarly challenging to interpret, as some aspects of neurogenesis like maturation are increased in Alzheimer’s Disease brains (Jin et al., 2004b) while other facets including proliferation and self-renewal are decreased in cultured cells derived from patients with Alzheimer’s disease in vitro (He and Shen, 2009).
Although the direction of the links between Alzheimer’s Disease and hippocampal neurogenesis await further validation, there is an active literature on strategies to promote new neurons with direct relevance for Alzheimer’s Disease (Schaeffer et al., 2009). Given the complexity of this disorder, future clinical studies likely will have to take a multipronged approach, such as assessing links between sleep, Alzheimer’s Disease, and neurogenesis (Meerlo et al., 2009).
Schizophrenia has among the most robust clinical evidence for a deficit in hippocampal volume (e.g. MacDonald and Schulz, 2009). In addition, there is an intriguing story developing on Disrupted-in-Schizophrenia-1 (DISC1), a schizophrenia susceptibility gene that also enhances susceptibility to other mental illnesses including MDD (Dranovsky and Hen, 2007; Welberg, 2009). DISC1 appears to be critical in neurogenesis (Enomoto et al., 2009; Kim et al., 2009; Maekawa et al., 2009b; Mao et al., 2009; Ming and Song, 2009), and has recently been found to be expressed in higher levels specifically in the hippocampi of patients diagnosed with schizophrenia (Nakata et al., 2009). Another gene linked to susceptibility of schizophrenia in humans is the bHLH transcription factor NPAS3 (Kamnasaran et al., 2003; Pickard et al., 2009). While it is intriguing that mice lacking NPAS3 in all cells from birth show deficits in hippocampal neurogenesis (Pieper et al., 2005), further assessment of links between NPAS3 and neurogenesis will benefit from cell-targeting strategies.
In addition to the requirement of DISC1 and NPAS3 for normal neurogenesis, there is ample preclinical evidence that schizophrenia is linked to decreased in vivo and in vitro neurogenesis (Table 1) (Arango et al., 2001; Kempermann et al., 2008; Kobayashi, 2009; Reif et al., 2007). For example, mice that constitutively lack NPAS3, that have a mutant form of DISC1, or that were administered phencyclidine display decreased in vivo proliferation and survival (Duan et al., 2007; Liu et al., 2006; Maeda et al., 2007; Pieper et al., 2005). In contrast, drugs that are used to counteract schizophrenic symptoms in people, like antipsychotics (clozapine), NMDA antagonists (memantine), acetylcholinesterase inhibitors (tacrine, donepezil, phenserin), and -secretase inhibitors (dibenzazepine, DAPT) in general enhance cells in discrete stages of neurogenesis in vivo and in vitro (Table 1) (Breunig et al., 2007; Jin et al., 2006; Kaneko et al., 2006; Kotani et al., 2008; Maeda et al., 2007; Maekawa et al., 2009a; Marutle et al., 2007; Namba et al., 2009; Wang et al., 2009). It is perhaps not surprising that a drug like DAPT actually enhances proliferation given that it also prevents cleavage of stem-cell promoting proteins like Notch1 (Breunig et al., 2007; Favaro et al., 2009).
Human work supports these links between schizophrenia and decreased hippocampal neurogenesis, as tissue from human schizophrenics has fewer proliferating Ki-67 cells than tissue from control subjects (Reif et al., 2006). However, caution is advised in the interpretation of Reif et al., because a decrease in Ki-67-expressing cells is not an index of overall neurogenesis, as not all dividing cells become neurons (Eisch and Mandyam, 2007). Even so, the links between hippocampal neurogenesis and schizophrenia are promising enough to inspire the proposition that an immature dentate gyrus, as might result from decreased neurogenesis, is a novel endophenotype of psychiatric disorders like schizophrenia (Yamasaki et al., 2008).
While Table 1 and the review above support the breadth and depth of neurogenesis as target for the treatment of mental illness, there are problems with hippocampal neurogenesis as a clinically-viable treatment. First, none of these psychiatric disorders is marked by overt loss of dentate gyrus granule neurons as a primary pathology. While both Alzheimer’s Disease and schizophrenia are incontrovertibly accompanied by hippocampal atrophy, decreased hippocampal volume may be correlative, and this atrophy is not regionally restricted to the dentate gyrus granule cell layer where adult neurogenesis occurs. Further, it remains unclear if a smaller hippocampus predisposes a person to these disorders. Second, the majority of these disorders and their pathophysiology are not, in fact, rooted in the hippocampus. As an example, symptomology of PTSD is coincident with structural and functional changes in the amygdala and cortex, which may play a more prominent role than the hippocampus (e.g. Lupien et al., 2007a). Third, increased numbers of adult-born neurons might not always better (Scharfman and Hen, 2007), and in fact stimulation of aberrant neurogenesis as in the epileptic brain may do more harm than good (Parent et al., 2007; Parent and Murphy, 2008).
Another major concern regards the potential for adult neurogenesis in the dentate gyrus to overcome generalized hippocampal atrophy. In some rodent experiments, antidepressant treatment reversed stress-induced decreases in hippocampal volume (e.g. tianeptine in Czeh et al., 2001); the behavioral effects of antidepressant treatment have been explored elsewhere. In rodent models, adult neurogenesis contributes approximately 5% of the total cells in the dentate gyrus (Lagace et al., 2007b); in humans, however, estimates of total contribution of neurogenesis remain unclear but are generally very low (e.g. Kornack and Rakic, 1999). Therefore, it seems unlikely that the relatively modest neurogenesis in the human could reverse the estimated 10–15% loss of total hippocampal volume observed in MDD clinically (Czeh and Lucassen, 2007). Therefore, while targeting atrophy seems a realistic treatment goal, we do not believe that normalization of neurogenesis alone would be sufficient to overcome atrophy.
This does not mean the concept of targeting adult hippocampal neurogenesis for the treatment of mental illnesses should be abandoned. Rather, the concept should be re-articulated in a more practical way: understanding hippocampal neurogenesis will give us a better understanding of brain plasticity in general, which then might be harnessed to tackle and perhaps prevent a wide variety of disorders, including psychiatric disorders. The next section details obstacles that need to be overcome in order for the translational application of hippocampal neurogenesis to become a reality.
Many obstacles stand in the way of fully harnessing hippocampal neurogenesis for the treatment of mental illness and other brain disorders. One of the most glaring knowledge gaps is the lack of understanding about differences between rodent and human neurogenesis. More specifically, almost nothing is known about human neurogenesis except that it persists into adulthood (Eriksson et al., 1998; Manganas et al., 2007). More information is needed on the extent of neurogenesis, the function of adult-generated neurons, the location and function of the adult stem cell, and even whether the stages of neurogenesis that are so well-characterized in the rodent are recapitulated in the human. We need to understand these fundamental concepts before we can fully appreciate how these dependent measures are changed in mental illness. For example, the recent pioneering study in human MDD patients examined the number of dividing Ki-67- and nestin-expressing cells (Boldrini et al., 2009). However, it remains to be proven in the human and even in the rodent brain whether nestin expression is a sufficient requirement to label the stem cells. We also need better understanding of how new neurons integrate into hippocampal circuitry. To this end, more functional approaches combined with computational modeling may provide critical insight (Gradin and Pomi, 2008). A more thorough examination of human post-mortem samples is also desperately needed to better understand human neurogenesis and how it is similar to, and distinct from, rodent neurogenesis.
On a related note, more work is needed on precisely what other neurogenic niches exist in the basal (Cameron and Dayer, 2008; Gould, 2007) or injured brain (Magavi and Macklis, 2002). Such information in the rat or mouse brain but especially in the human brain would be immensely useful for understanding the etiology of mental illnesses as well as delineating treatment options and limitations. The importance of the niche reminds us that while in vitro work will remain invaluable for the mechanistic insight it can provide to us about adult hippocampal neurogenesis, it is necessary to pursue as much work in vivo or in situ as possible. In fact, there is growing appreciation that while “stem cell genes” have been identified, the concept of “stemness” in fact may rely solely on the niche in which the cell develops (Lander, 2009). Powerful new tools for imaging new neurons in the living brain are likely to help bridge this knowledge gap (Manganas et al., 2007; Pereira et al., 2007), and such data would bring us closer to being able to direct new neurons to places of primary pathology in each disease, and to design approaches to specifically target select stages of neurogenesis.
It is also critical to improve our fundamental understanding of mental illnesses and their pharmacological treatments (Dhikav and Anand, 2007), and to parlay key aspects of the disorders into common use in basic animal models. For example, one key assessment lacking in the MDD and PTSD literature is whether there is a heterogeneous response of neurogenesis to stress, though a heterogeneous behavioral response has been described (Krishnan et al., 2007). Given the differences in allostatic load according to experience (McEwen, 2007), examination of whether neurogenesis is correlated with – or perhaps causative to – the development of individual susceptibility or resilience to stress is a high priority for the field.
A more complete understanding of disease pathophysiology and neuromechanisms of effective treatments will also require additional and more complete model systems. For example, the prairie vole has a well-delineated social structure and can provide an excellent model for depression, anxiety, social isolation, and perhaps even PTSD (e.g. Grippo et al., 2008). Also, recently-developed mouse models to track and inducibly manipulate stem cells and their progeny need to be incorporated with existing disease models to greatly advance our understanding of the complex interplay between disease models and neurogenesis (Lagace et al., 2007b; Mori et al., 2006). Even more commonly-used approaches to suppress hippocampal neurogenesis, like cranial irradiation, are proving very useful in uncovering novel roles for adult neurogenesis in psychiatric disorders like addiction (Noonan et al., in press). Perhaps using such approaches more widely and rigorously will allow us to learn more about how we might encourage migration of SGZ-generated neurons into nearby regions, as has been shown in other brain regions (Yamashita et al., 2006). This would potentially allow directed migration of adult-generated neurons to the site of pathology in each brain disorder, vastly enhancing the utility of this approach for translational use.
Another critical obstacle to address is the differences in incidence and treatment of mental disorders by sex. It is clear that sex steroids exert potent influences on the dentate gyrus physiology and in stress responses (Goel and Bale, 2009; Hajszan et al., 2007). For example, sex appears to play a critical role in mental disorders and in regulation of neurogenesis in the rat and human (Boldrini et al., 2009; Galea, 2008). As the mouse is a major model species in neuroscience, it is notable that evidence for sex differences in the mouse remains inconclusive (Lagace et al., 2007a; Sakata et al., 2009; Silasi et al., 2004). Given the demonstrated implications that phytoestrogens have on laboratory animal and human cognition and behavior (e.g. Lephart et al., 2002; Patisaul and Polston, 2008), it will be critical for future preclinical studies to account for phytoestrogens in laboratory animal chow as this will make translational application of the data more feasible.
While many of the obstacles noted above relate to human neurogenesis and translational efforts, one final obstacle falls squarely in the realm of the basic researchers. We also need a more complete understanding the function of adult-generated neurons, and the dentate gyrus as a whole. This likely will emerge as researchers employ better models of inducible and reversible ablation of neurogenesis (e.g. Dupret et al., 2008; Saxe et al., 2006; Singer et al., 2009), and as cleaner and more sophisticated ways to assess hippocampal function in behavioral tasks are developed.
Even if adult hippocampal neurogenesis is not an immediate target for the amelioration of the symptoms and trajectory of mental disorders, it does makes sense both to study it and harness it where feasible and practical, and to in general promote hippocampal health. Indeed, driving hippocampal neurogenesis is tightly correlated with other things presumed to be good for the hippocampus, such as angiogenesis, blood flow, and growth factor production and cytokine reduction (e.g. Pereira et al., 2007). We offer a few words on this topic in order to highlight some commonly-used approaches as well as developing techniques to enhance neurogenesis.
One of the most clear-cut ways to both enhance adult hippocampal neurogenesis and thus perhaps hippocampal plasticity and health is via exercise (Fabel and Kempermann, 2008; Pietropaolo et al., 2008; van Praag, 2008). For example, exercise is an effective antidepressant, and it enhances neurogenesis even under conditions of forced exercise. Environmental enrichment, also referred to as environmental complexity, is another robust way of promoting neurogenesis and hippocampal plasticity. Interestingly, environmental enrichment and voluntary exercise promote hippocampal neurogenesis via dissociable pathways (Olson et al., 2006), indicating there are likely multiple pathways to enhanced neurogenesis that remain to be understood. These strong links between exercise and enhanced neurogenesis are quite clinically compelling since exercise is an effective treatment for many mental disorders, including MDD and Alzheimer’s Disease (Andrade and Radhakrishnan, 2009; Mead et al., 2009).
On a molecular basis, it will be increasingly important to identify cell-intrinsic and niche factors important to discrete stages of neurogenesis, such as the recently identified Cdk5, NeuroD, Sox2, Notch, and CREB (Favaro et al., 2009; Gao et al., 2009; Jagasia et al., 2009; Lagace et al., 2008). CREB is particularly intriguing in this regard because it drives brain derived neurotrophic factor (BDNF), a factor strongly correlated with neurogenesis in animal models and decreased in post-mortem tissue from MDD patients (Brunoni et al., 2008; Duman, 2004). A final approach that may be utilized to drive adult neurogenesis is the application of stem cell technology to enhance neurogenesis, either via viral-mediated gene transfer or nanoparticles as has been done for other stem cell populations (e.g. Brown and Naldini, 2009; Yang et al., 2009).
Because the primary pathology in MDD, PTSD, schizophrenia and Alzheimer’s Disease is not an early and overt loss of dentate gyrus granule cells, it is obvious that dentate gyrus granule cell replacement strategies via stimulation of adult hippocampal neurogenesis alone will not be sufficient for treatment of these disorders. However, the general consensus among researchers and physicians is that activities that promote overall health and wellness, such as physical and mental exercises, are beneficial to hippocampal health and can help prevent or combat mental illness (e.g. Valenzuela et al., 2008). As these activities enhance neurogenesis in animal models, they may very well enhance neurogenesis in humans too. Thus, the advancement of our understanding of adult hippocampal neurogenesis has and will likely continue to reveal neuromechanisms of plasticity that can then be co-opted for translational application to these and other disorders, such as addiction and epilepsy, to help restore or enhance hippocampal plasticity.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.